Pancragen peptide: what the Khavinson pancreatic tetrapeptide is, what the studies show and what is unknown

Pancragen is the trade name for the tetrapeptide Lys-Glu-Asp-Trp: lysine, glutamic acid, aspartic acid and tryptophan in that order, written KEDW in single-letter code, so the KEDW peptide and pancragen are the same molecule. Several of the developers’ papers give the structure as H-Lys-Glu-Asp-Trp-NH2, or KEDWa, meaning the tryptophan carboxyl group is converted to an amide; they explain that the amide was chosen to protect the peptide from digestive enzymes ^{[1] [5]}. Research suppliers usually list the sequence without specifying whether their product is the free acid or the amide, which is worth asking about, since the two differ in mass by about one dalton.

Unlike most Khavinson peptides, which were designed from the amino acid composition of an organ extract, pancragen has a stated rational origin. A 2005 paper by Vladimir Khavinson reported that an analysis of the amino acid sequences of insulinotropic polypeptides revealed a common four-residue fragment, and that KEDWa was synthesised as a protease-protected analogue of that fragment ^[1]. It is grouped with the other tissue-specific short peptides from the St Petersburg Institute of Bioregulation and Gerontology: vilon for the thymus, epitalon for the pineal gland, vesugen for blood vessels, livagen for the liver and bronchogen for the lungs. Sellers describe it as the pancragen bioregulator or pancreas peptide.

Almost all published work on pancragen has Khavinson among the authors. The English-language papers appeared in the Bulletin of Experimental Biology and Medicine, a translated Russian journal indexed in PubMed; the monkey studies and one cell study are in Advances in Gerontology, a Russian journal with English abstracts only. No laboratory independent of the developers has, to our knowledge, published on KEDW. That context applies to every result below.

The proposed mechanism is direct action on gene expression in pancreatic cells. In the 2005 rat study, the authors suggested that the tetrapeptide activates the promoter of the preproinsulin gene by complementary interaction with the sequences GGCAGG and CCTGCC in DNA ^[1]. A 2014 molecular mechanics study modelled Lys-Glu-Asp-Trp binding to both the minor and major grooves of DNA and proposed GGCAG as its binding site, noting that binding in the major groove is sequence-dependent ^[8]. In a 2013 test-tube study, Lys-Glu-Asp-Trp was one of six short peptides shown to bind fluorescently labelled wheat histones H1, H2B, H3 and H4, apparently at their N-terminal tails ^[12].

Cell-culture work from the same group fits this picture. In cultures of human pancreatic cells, KEDW increased the expression of the differentiation factors Pdx1 and Ptf1a in acinar cells and Pdx1, Pax6, Pax4, Foxa2 and Nkx2.2 in islet cells, in both young and aged cultures; the authors proposed that inducing pancreatic cell differentiation is the mechanism behind its anti-diabetic and anti-inflammatory effects ^[7]. In aged pancreatic cell cultures, the tetrapeptide raised MMP2, MMP9, serotonin, CD79alpha, the anti-apoptotic protein Mcl1 and the proliferation markers PCNA and Ki-67, and reduced p53 ^[5]. In a comparison across tissues, pancragen stimulated CXCL12 and Hoxa3 in pancreatic cells but bronchogen and vesugen did so in bronchial cells and fibroblasts respectively, which the authors present as evidence of tissue specificity ^[6]. The developers’ 2020 review lists KEDW as an inducer of pancreatic cell differentiation ^[13].

All of this is from one group and rests on culture and computer modelling. The DNA-binding hypothesis has not been tested by chromatin immunoprecipitation or any method that would show the peptide at the proposed sequence in a living cell, and no receptor for KEDW has been identified. An alternative reading of the animal data, that a tryptophan-containing tetrapeptide affects insulin release or glucose handling by a more conventional route, has not been excluded.

Blood sugar in diabetic rats: the 2005 study reported that KEDWa partially restored insulin synthesis in rats with alloxan-induced diabetes, and that the slope of their glucose curve became similar to that of normal animals ^[1]. A 2007 study in rats with streptozotocin-induced diabetes found that oral pancragen produced a pronounced fall in blood glucose during treatment, and that intramuscular pancragen normalised the adhesion of capillary endothelium in the mesentery without changing capillary permeability ^[2]. A 2010 paper assessed the tetrapeptide through the course of development and in streptozotocin diabetes using a panel of metabolic markers of apoptosis; its abstract does not give the results ^[3].

Glucose tolerance in old monkeys: two studies from the Sochi primate centre are the strongest animal evidence in the series. In 2014, old female rhesus monkeys, which showed slower glucose clearance and exaggerated insulin and C-peptide peaks compared with young animals, were given 50 µg of pancragen per animal per day intramuscularly for 10 days; glucose disappearance sped up markedly and the insulin and C-peptide responses normalised, with the effect partly persisting three weeks after the last dose ^[9]. In 2015, nine old monkeys were split between pancragen (0.05 mg per animal per day, intramuscular, 10 days) and the sulphonylurea glimepiride (4 mg per day by mouth). Both lowered fasting glucose; pancragen also normalised insulin and C-peptide, whereas glimepiride produced a stronger, more delayed glucose fall and stimulated C-peptide without changing insulin ^[10]. Five monkeys is a very small group, and there was no placebo arm, but this is the only primate data for any peptide in the Khavinson series.

Tissue culture: at 0.05 ng/mL, pancragen stimulated the growth of pancreas explants from young and old rats, while cardiogen, bronchogen and prostamax did the same for heart, lung and prostate explants respectively ^[11]. The pancreatic cell studies above report increased differentiation markers and proliferation and reduced apoptosis in ageing cultures ^{[5] [7]}.

What has not been studied is as important as what has. There is no study of pancragen in obese or insulin-resistant animals with normal pancreatic function, no study of body weight, no study comparing it with incretin drugs such as semaglutide, and no study of long-term dosing. The claim sometimes made that pancragen is a natural alternative to GLP-1 medicines has no comparative evidence behind it; the monkey comparison was with glimepiride, a sulphonylurea, and favoured a different profile rather than superiority ^[10].

We found one human study. In 2011, Korkushko, Khavinson and colleagues at the Institute of Gerontology in Kyiv examined 30 healthy older people and 33 older patients with type 2 diabetes. The diabetic patients had night-time melatonin production about 70% lower than the healthy group. In patients given pancragen, fasting glucose, glucose during a standard tolerance test, plasma insulin and the insulin resistance index all fell significantly, while patients who did not receive pancragen showed no change in carbohydrate metabolism. The authors concluded that impaired pineal melatonin production contributes to insulin resistance in older people and that pancragen is a promising way to correct it ^[4].

That is a real clinical observation, but it is not a controlled trial. The English abstract does not describe randomisation, blinding or a placebo, does not state the dose, route or duration, and does not report side effects. The comparison group appears to be patients who simply did not receive the peptide. Any of the usual biases, including extra attention to the treated group, dietary change and regression to the mean, could account for the improvements. No follow-up trial has been published in the fifteen years since, and there is no pancragen entry on ClinicalTrials.gov as of September 2026.

The developers’ own cell studies cite a clinical effect in elderly patients with type 2 diabetes as established fact ^[5], but the only source for that effect is the 2011 report. The honest position is that pancragen diabetes claims rest on rats, five to nine monkeys and one uncontrolled human study, all from a single research network.

In the monkey studies, fasting glucose and glucose tolerance changed within a 10-day course of daily injections, and the improved tolerance partly persisted three weeks after stopping ^{[9] [10]}. In diabetic rats, oral pancragen lowered blood glucose during the treatment period ^[2]. The human report does not state how long patients were treated before measurement ^[4]. No study has measured how long any effect lasts in people.

The figures below describe what published studies used. They are not recommendations, and no human dose has been established in a controlled trial. In old rhesus monkeys, pancragen was given at 50 µg (0.05 mg) per animal per day by intramuscular injection for 10 days ^{[9] [10]}; an adult female rhesus weighs roughly 5 to 8 kg, so that is on the order of 6 to 10 µg/kg. In rats, it was given orally or intramuscularly, at doses not stated in the abstract ^[2]. In culture, 0.05 ng/mL stimulated pancreas explants ^[11]. The human report does not give a dose ^[4].

Research suppliers sell pancragen as a lyophilised powder, usually in 10 to 20 mg vials, and Russian supplement versions are sold as capsules; neither quantity comes from a dose-finding study, and a 10 mg vial contains about 200 times the daily monkey dose. For converting vial contents to a concentration for a laboratory protocol, use the peptide calculator or the pancragen calculator page.

Pancragen has been given orally and intramuscularly to rats ^[2] and intramuscularly to monkeys ^{[9] [10]}. The amidated form was designed specifically to survive gut proteases, and the 2007 rat study is one of the few in the Khavinson series to report an effect after oral dosing ^{[1] [2]}. The developers have also modelled absorption of their short peptides through the intestinal transporters LAT1, LAT2 and PEPT1 ^[14]. Even so, no pharmacokinetic study has measured pancragen in the blood of any species after any route, so oral bioavailability, half-life and distribution are unknown.

Because the amide and free-acid forms differ by about one dalton, and because pancragen contains tryptophan, which is prone to oxidation, a certificate of analysis should report the exact measured mass and the purity by HPLC. A mass near 576.6 indicates the free acid, one near 575.6 the amide; either may be sold as pancragen.

No systematic safety study of pancragen exists. The monkey authors describe it as effective and safe for correcting age-related pancreatic dysfunction, but that judgement rests on nine animals treated for 10 days ^[10]. The human report does not mention adverse events ^[4]. So the ordinary questions, whether pancragen causes hypoglycaemia, nausea, weight change or interactions, have no evidence-based answers.

Two concerns follow from what is claimed. First, if the peptide lowers glucose and insulin resistance in people with type 2 diabetes as reported ^[4], then adding it to insulin or sulphonylureas without monitoring carries a hypoglycaemia risk; if it does not, the report is wrong, and either way self-experimentation in someone on glucose-lowering medicines is hazardous. Second, the developers describe pancragen as stimulating proliferation and suppressing p53 and apoptosis in ageing pancreatic cells ^{[5] [7]}; whether a peptide with that profile is neutral for pancreatic tumour risk over long-term use has never been examined. Pancragen is not on the FDA’s list of compounding bulk substances that may present significant safety risks ^[15]; that reflects that nobody nominated it, not that it has been reviewed.

Pancragen is not an approved medicine in the UK, US, EU, Canada or Australia. A product marketed for human use with claims about blood sugar or diabetes would be treated as a medicine in the UK regardless of a research-use label, and the MHRA has licensed no such product. In the US it is not an FDA-approved drug and has not appeared on the compounding category 2 list ^[15]. In Russia it is sold as a dietary supplement rather than a registered medicine, which confers no status elsewhere. We have not confirmed its standing under the WADA Prohibited List.

For the rules on buying and holding research peptides in your country, see the legal status overview, the UK page, the US page and the Canada page.

Pancragen is supplied as a freeze-dried powder. Its tryptophan residue makes it more sensitive to light and oxidation than the other KED-family peptides, so keeping the sealed vial cold, dry and in the dark matters more here. Refrigerate any reconstituted solution and use it within a limited period. See how to store peptides and the bacteriostatic water guide.

A four-amino-acid peptide is cheap to synthesise, so price says little about quality. Compare pancragen prices across the stores we track, including UK listings and US listings. Read how to read a peptide COA first and check the measured mass against the two possible forms described above. Our third-party tested suppliers list shows which stores publish independent tests, and the third-party testing guide explains what those tests do and do not prove.

Sellers often group pancragen with other metabolic products such as MOTS-c or AOD-9604, or with the other Khavinson peptides, thymalin, pinealon and cartalax. For a general orientation, see what research peptides are and how to spot a fake peptide supplier.